




DECEMBER 2025 SNAPSHOT UPDATE

HEPATITIS C:
STATE OF
MEDICAID
ACCESS



A+ (20):

Colorado, Delaware, Idaho, Kansas, **Maine**, Michigan, Missouri, New Hampshire, **New Jersey**, **New Mexico**, New York, North Carolina, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, Virginia, Washington, Wisconsin

A (15):

Alaska, Arizona, California, Connecticut, **District of Columbia**, **Florida**, Hawaii, Illinois, Indiana, **Iowa**, Louisiana, Massachusetts, **Minnesota**, **Puerto Rico**, South Dakota

B (10):

Alabama, **Arkansas**, Kentucky, Mississippi, Ohio, South Carolina, Tennessee, Vermont, **West Virginia**, Wyoming


C (7):

Georgia, Maryland, Montana, Nebraska, Nevada, North Dakota, Utah

D (0)

F (0)


States with updated grades since the 2024 Snapshot Update are in **BOLD**.



No Prior Authorization for Most Patients (34):
Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Hawaii, Idaho, Illinois, Indiana, **Iowa**, Kansas, Louisiana, **Maine**, Massachusetts, Michigan, **Minnesota**, Missouri, New Hampshire, **New Jersey**, **New Mexico**, New York, North Carolina, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, Virginia, Washington, **West Virginia**, Wisconsin

Prior Authorization Required (18):
Alabama, Arkansas, Georgia, Kentucky, Maryland, Mississippi, Montana, Nebraska, Nevada, North Dakota, Ohio, Puerto Rico, South Carolina, South Dakota, Tennessee, Utah, Vermont, Wyoming


*States that have been recategorized since the 2024 Snapshot Update are in **BOLD**.*



No Fibrosis Restrictions (52):

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

*States that have been recategorized since the 2024 Snapshot Update are in **BOLD**.*



No Substance Use Restriction (46):

Alabama, Arizona, **Arkansas**, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, **Iowa**, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, **Minnesota**, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin, Wyoming


*States that have been recategorized since the 2024 Snapshot Update are in **BOLD**.*

Provider Must Address and/or Counsel Patient About Substance Use Issues Prior to Treatment (6):

Alaska, Mississippi, Montana, Nebraska, North Dakota, West Virginia

Substance Use Restriction Prior to or During Treatment, Including Abstinence and Mandatory SUD Treatment (0):

None



No Prescriber Restrictions (49):

Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Georgia, Hawaii, Idaho, Indiana, **Iowa**, Louisiana, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

*States that have been recategorized since the 2024 Snapshot Update are in **BOLD**.*


Prescription by or in Consultation with a Specialist (3):

Arkansas, Illinois, Nevada



HEPATITIS C
STATE OF MEDICAID ACCESS

RETREATMENT
DECEMBER 2025



Note: states are not penalized for requiring prior authorization for retreatment.

No Retreatment Restrictions (40):

Alaska, **Arkansas**, Colorado, Connecticut, District of Columbia, Delaware, Hawaii, Idaho, Illinois, **Iowa**, Kansas, Louisiana, **Maine**, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin

Retreatment Restrictions based on adherence, substance use, or SVR12 documentation (12):


Alabama, Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Montana, North Dakota, West Virginia, Wyoming

*States that have been recategorized since the 2024 Snapshot Update are in **BOLD**.*



HEPATITIS C STATE OF MEDICAID ACCESS

MANAGED CARE DECEMBER 2025



No Additional Restrictions in Managed Care (36):

Arkansas, Arizona, California, Colorado, Delaware, **Florida**, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, **Maryland**, Massachusetts, Michigan, Mississippi, Missouri, New Hampshire, **New Jersey**, New Mexico, New York, North Carolina, North Dakota, Ohio, **Oklahoma**, Oregon, Pennsylvania, Puerto Rico, Rhode Island, **South Carolina**, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin

Additional Restrictions and/or Lack of Transparency in Managed Care (7):

District of Columbia, Georgia, Hawaii, **Minnesota**, Nebraska, Nevada, Utah

N/A, State Doesn't Contract With Managed Care (9):

Alabama, Alaska, Connecticut, Idaho, Maine, Montana, South Dakota, Vermont, Wyoming

*States that have been recategorized since the 2024 Snapshot Update are in **BOLD**.*



Citation: Center for Health Law and Policy Innovation & National Viral Hepatitis Roundtable, Hepatitis C: State of Medicaid Access (2025), www.stateofhepc.org

Hepatitis C: State of Medicaid Access is supported by AbbVie and Gilead Sciences. The methods, research, and conclusions of this project are those of the Center for Health Law and Policy Innovation of Harvard Law School and National Viral Hepatitis Roundtable and do not necessarily reflect the opinions of AbbVie or Gilead Sciences.

About CHLPI: The Center for Health Law and Policy Innovation of Harvard Law School advocates for legal, regulatory, and policy reforms to improve the health of marginalized populations, with a focus on the needs of low-income people living with chronic illnesses and disabilities. CHLPI works to expand access to high-quality health care; to reduce health disparities; to develop community advocacy capacity; and to promote more equitable and effective health care systems. CHLPI is a clinical teaching program of Harvard Law School and mentors students to become skilled, innovative, and thoughtful practitioners as well as leaders in health and public health law and policy. For more information, visit www.chlpi.org.

About NVHR: An initiative of the HEP, NVHR is the largest network of patients, providers, public health leaders, and community partners breaking down barriers to care across the United States. For over 20 years, we have driven progress toward viral hepatitis elimination through knowledge sharing, advocacy, and policy change. For more information, visit www.nvhr.org.